BioNTech Investor Presentation Deck

We Collaborate with Global Leaders in Our Industry COVID-19 Vaccine 50:50 gross profit share¹ 2Pfizer 12 FOSUNPHARMA Fix Vac Melanoma Companies keep full rights to own product Collaborations for clinical stage programs Bispecific mABs 50:50 cost & profit share Genmab REGENERON Shingles Cost and gross profit share 2Pfizer iNeST 50:50 cost & profit share Genentech Pre-clinical collaborations Up to 10 Infectious Disease Indications worldwide opt-in right University of Pennsylvania 150:50 cost & profit share refers to terms of Pfizer collaboration only (world-wide ex-China) HIV, Tuberculosis developed world rights BILL & MELINDA GATES foundation Intra-tumoral mRNA cost & profit share SANOFI Seasonal Influenza royalties & milestones Pfizer 5 Rare Disease Indications 50:50 cost & profit share GENEVANT BIONTECH

View entire presentation